News | May 20, 2023
Abbott India posts Q4FY23 PAT at Rs. 231.42 Cr
The company has reported total income of Rs. 1392.72 crores during the period ended March 31, 2023
The company has reported total income of Rs. 1392.72 crores during the period ended March 31, 2023
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
Stedycon Sted super-resolution fluorescence microscope
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes – detecting four infections simultaneously
Vacuum-Assisted Breast Biopsy (VABB) is an innovative and more effective alternative to the traditional method where benign lumps are removed surgically, leaving scars and causing distress
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Subscribe To Our Newsletter & Stay Updated
